{
    "medicine_id": "74bba43201b73f4ae6623436bfb52c6a1860affe",
    "platform_id": "9861",
    "metadata": {
        "name": "Nevirapine Mylan 200 mg tablets",
        "composition": "Each tablet contains 200 mg of nevirapine anhydrous",
        "clinical_particulars": {
            "therapeutic_indications": "Nevirapine Mylan is indicated in combination with other anti retroviral medicinal products for treatment of HIV 1 infected adults adolescents and children of any age see section 4 2 Most of the experience with nevirapine is in combination with nucleoside reverse transcriptase inhibitors NRTIs The choice of a subsequent therapy after Nevirapine Mylan should be based on clinical experience and resistance testing see section 5 1",
            "contraindications": {
                "disease": "Hypersensitivity to the active substance or to any of the excipients listed in section 6 1 Nevirapine must not be re administered to patients who have required permanent discontinuation for severe rash rash accompanied by constitutional symptoms hypersensitivity reactions or clinical hepatitis due to nevirapine Nevirapine must not be used in patients with severe hepatic impairment Child Pugh C or pre treatment ASAT or ALAT 5 ULN until baseline ASAT ALAT are stabilised 5 ULN Nevirapine must not be re administered in patients who previously had ASAT or ALAT 5 ULN during nevirapine therapy and had recurrence of liver function abnormalities upon re administration of nevirapine see section 4 4 Herbal preparations containing St John s Wort Hypericum perforatum must not be used while taking Nevirapine Mylan due to the risk of decreased plasma concentrations and reduced clinical effects of nevirapine see section 4 5",
                "pregnancy": "Applicable",
                "machine_ops": "Applicable",
                "excipients": "Lactose monohydrate;Microcrystalline cellulose (E460);Povidone (E1201) (K30);Sodium starch glycolate (Type A);Silica colloidal anhydrous (E551);Magnesium stearate (E572)",
                "incompatibilities": "Not applicable."
            }
        },
        "revision_date": "2021-08-12"
    }
}